To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Tryvio

Aprocitentan
Antihypertensive
Tablet

Tryvio is an oral tablet that lowers blood pressure in adults whose hypertension isn’t managed well despite using multiple medications. It blocks endothelin receptors to relax blood vessels, reducing risks of stroke and heart attack.

Approval Date
19-Mar-24
NCE-1 Date
19-Mar-28
NCE Date
19-Mar-29
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
33
2027
52
2028
72
2029
88
2030
92
2031
96
2032
98
Molecule profile

Details & specifications

Molecule
Aprocitentan
Innovator
IDORSIA PHARMACEUTICALS LTD
Dosage Form
Tablet
Strength
12.5 mg
Therapeutic Category
Antihypertensive
Usage
To treat hypertension
Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data
Milestones tracked against primary FDA sources and refreshed continuously.
Analyst-built projections
Seven-year sales outlooks modeled by our pharma intelligence team.
First-to-file focus
Exclusivity windows framed around the decisions generics teams actually make.
Partnership on demand
From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?